Overview

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

Status:
RECRUITING
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.
Phase:
PHASE2
Details
Lead Sponsor:
Narrows Institute for Biomedical Research
Collaborator:
Sun Pharmaceutical Industries Limited
Treatments:
Clascoterone